secwatch.observer — SEC 8-K summary
======================================

Issuer:     EAGLE PHARMACEUTICALS, INC. (—)
CIK:        0000827871
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001104659-24-061683
Event type: debt
Sentiment:  negative
Materiality: 0.80
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eagle Pharmaceuticals extends financial statement deadline to Jul 31, 2024; revolver cut to $50M
--------------------------------------------------------------------------------

- Annual audited 2023 financials, restated Q2 2023, Q3 2023, and Q1 2024 statements due July 31, 2024, per Third Amendment.
- Revolving commitment permanently reduced from $100M to $50M; availability restriction superseded by permanent cut.
- Minimum liquidity covenant reduced from $50M to $10M; prior liquidity covenant waiver terminated.
- Covenant flexibility restriction continues until all financials delivered; failure to meet deadline is an event of default.
- Credit obligations secured by substantially all assets; default could lead to acceleration and foreclosure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/827871/000110465924061683/0001104659-24-061683-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/827871/000110465924061683/tm2414362d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-061683

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer